MMCM
VERV

Murphy & Mullick Capital Management’s Verve Therapeutics VERV Stock Holding History

Murphy & Mullick Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-43
Closed -$197 – 703
2025
Q1 		$197 Hold
43
– – ﹤0.01% 652
2024
Q4 		$243 Buy
+43
New +$243 ﹤0.01% 639

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Murphy & Mullick Capital Management's VERV Position: Q2 2025 in Review

Murphy & Mullick Capital Management sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 43 shares — an estimated $197 sold.

Murphy & Mullick Capital Management first reported a position in VERV in Q4 2024 and held it in 2 quarters. The position peaked at $243 in Q4 2024. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Murphy & Mullick Capital Management reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Murphy & Mullick Capital Management sold 43 Verve Therapeutics shares in Q2 2025, an estimated $197.
  • Murphy & Mullick Capital Management first reported a position in Verve Therapeutics in Q4 2024 and held it in 2 quarters.
  • Murphy & Mullick Capital Management's Verve Therapeutics position peaked at $243 in Q4 2024.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.